Humana (HUM) News Today

Humana Inc. (NYSE: HUM) shares have weakened as investors weigh changes to the company’s Medicare Advantage offerings and mixed earnings revisions. The most immediate concern is whether plan changes, membership reductions and medical-cost trends will pressure profitability during the 2027 enrollment cycle.

• Positive Sentiment: Zacks Research raised its Humana 2026 EPS estimate to $9.05 from $9.00 and increased its 2027 forecast to $11.23 from $10.98. It also modestly improved its Q3 2026 estimate to a loss of $1.13 per share from $1.18, suggesting some near-term earnings expectations have stabilized. Zacks nevertheless maintained a “Hold” rating.
• Positive Sentiment: Humana said it will maintain affordable Medicare Advantage plans for 2027 while expanding specialized-care options, including offerings aimed at seniors with complex needs. The strategy could support member retention and strengthen the company’s positioning in key Medicare markets. Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
• Neutral Sentiment: Humana is scheduled to report third-quarter results on November 6, during Medicare Advantage open enrollment. Investors may focus on enrollment changes, plan pricing, medical utilization and the outlook for 2027 profitability. Humana Reports Third-Quarter Earnings Nov. 6
• Negative Sentiment: Zacks cut its Q3 2028 EPS estimate to $6.58 from $6.73 and reduced its FY2028 forecast to $29.45 from $30.30. It also slightly lowered its Q4 2026 estimate, highlighting longer-term uncertainty despite the improved 2026 and 2027 forecasts.
• Negative Sentiment: Reports on Humana’s 2027 Medicare Advantage expansion indicated that the stock was under pressure as investors assessed plan exits, benefit adjustments and potentially higher member costs. Those changes could weigh on enrollment growth and margins if members switch plans or utilization rises. Humana Expands Medicare Advantage Options for 2027

The Humana AB takeover and management reports referenced in some items concern the Swedish company Humana AB, not Humana Inc. (NYSE: HUM), and therefore are not relevant to this stock.